Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

49.96 -0.56 (-1.11%)
Official Closing Price Updated: 7:00 PM EDT, Sep 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,036,224
Open 50.72
Bid (Size) 49.96 (1)
Ask (Size) 50.03 (1)
Prev. Close 50.52
Today's Range 49.55 - 50.75
52wk Range 39.35 - 62.00
Shares Outstanding 2,222,113,553
Dividend Yield 4.56%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than... 
Via Benzinga
Topics Economy
Exposures Interest Rates
2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High
Rebounding growth could make shares of this leading drugmaker a big winner. 
Via The Motley Fool

Performance

YTD
-5.31%
-5.31%
1 Month
+4.98%
+4.98%
3 Month
+21.14%
+21.14%
6 Month
-6.41%
-6.41%
1 Year
-17.61%
-17.61%

More News

Read More
2 No-Brainer Large-Cap Stocks to Buy With $500 Right Now
Via The Motley Fool
Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
From Bristol Myers Squibb
Via Business Wire
Market Whales and Their Recent Bets on BMY Options
Via Benzinga
Key Takeaways From Bristol-Myers Squibb Analyst Ratings
Via Benzinga
Bristol-Myers Squibb's Options Frenzy: What You Need to Know
Via Benzinga
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Via Benzinga
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
Via Benzinga
Kohl's Posts Upbeat Q2 Earnings, Joins Box, Waldencast, AeroVironment And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Check Out What Whales Are Doing With BMY
Via Benzinga
Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers
Via Investor's Business Daily
3 High-Yield Dividend Stocks With Payout Ratios Below 75%
Via The Motley Fool
2 Beaten-Down S&P 500 Dividend Stocks to Buy on the Dip and Hold Forever
Via The Motley Fool
Topics Stocks
Exposures US Equities
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
Via Benzinga
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
From Bristol Myers Squibb
Via Business Wire
Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer
Via Benzinga
Exposures Product Safety
Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma
From Bristol Myers Squibb
Via Business Wire
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
3 High-Yield Dividend Stocks You Can Buy With $200 Now and Hold at Least a Decade
Via The Motley Fool
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
From Bristol Myers Squibb
Via Business Wire
Where Will Bristol Myers Squibb Be in 5 Years?
Via The Motley Fool
3 High-Yield Dividend ETFs to Buy to Generate Passive Income
Via The Motley Fool
Topics ETFs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.